Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
Launched by SUZHOU ALPHAMAB CO., LTD. · Dec 12, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new medication called KN060 to see how well it prevents blood clots in patients who are having total knee replacement surgery, also known as total knee arthroplasty (TKA). The trial is comparing KN060 to a commonly used blood thinner called enoxaparin to determine which is safer and more effective at preventing clotting during recovery from surgery.
To be eligible for this study, you need to be between 18 and 75 years old and planning to have a total knee replacement. It's important that you are not at high risk for bleeding or have certain medical conditions, like recent heart attacks or strokes, or a history of blood clots. If you decide to participate, you’ll need to sign a consent form to show that you understand the study. Throughout the trial, you will be monitored closely to ensure your safety and to see how well the medication works. This trial is currently recruiting participants, and both men and women are welcome to join.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or female, aged between 18 and 75 years old (including the cut-off value);
- • 2. undergoing unilateral Total Knee Arthroplasty (TKA);
- • 3. Voluntarily participate in the study and sign a written informed consent;
- Exclusion Criteria:
- 1. There is a high risk of bleeding or abnormal bleeding related indicators:
- • 2. Evidence of venous thrombosis, such as the presence of related symptoms or auxiliary tests indicating thrombosis; Or have a history of venous embolic disease.
- • 3. Acute myocardial infarction or ischemic stroke occurred within 6 months before screening.
- • 4. Presence of malignant tumors or history of malignant tumors.
About Suzhou Alphamab Co., Ltd.
Suzhou Alphamab Co., Ltd. is a leading biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, particularly in the fields of oncology and autoimmune diseases. Established with a commitment to advancing healthcare, Alphamab leverages cutting-edge technologies, including monoclonal antibodies and novel drug delivery systems, to create targeted therapies that address unmet medical needs. With a robust pipeline of clinical trials and a dedication to scientific excellence, the company aims to enhance patient outcomes and contribute to the global biotechnology landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Trial Officials
Xianlong Zhang, Doctor
Principal Investigator
Shanghai 6th People's Hospital
Feng Yin, Doctor
Principal Investigator
Shanghai East Hospital of Tongji University
Zhenjun Yao, Doctor
Principal Investigator
Fudan University
Shijun Gao, Doctor
Principal Investigator
Hebei Medical University Third Hospital
Jun Lu, Doctor
Principal Investigator
Zhongda Hospital
Xinshe Zhou, Doctor
Principal Investigator
The First Affiliated Hospital Of Bengbu Medicai College
Rende Ning, Doctor
Principal Investigator
Hefei First People's Hospital
Lidong Wu, Doctor
Principal Investigator
Second Affiliated Hospital, School of Medicine, Zhejiang University
Wenming Zhang, Doctor
Principal Investigator
First Affiliated Hospital of Fujian Medical University
Yayi Xia, Doctor
Principal Investigator
Lanzhou University Second Hospital
Song Chen, Doctor
Principal Investigator
The Third Hospital of Changsha
Tan Lu, Doctor
Principal Investigator
The First Affiliated Hospital Of Xingxiang Medical University
Chunming Huang, Doctor
Principal Investigator
The People's Hospital of Gaozhou
Jun Xiao, Doctor
Principal Investigator
Tongji Hospital
Pengde Kang, Doctor
Principal Investigator
West China Hospital
Min Dai, Doctor
Principal Investigator
The First Affiliated Hospital of Nanchang University
Wei Huang, Doctor
Principal Investigator
First Affiliated Hospital of Chongqing Medical University
Jiangwei Li, Doctor
Principal Investigator
The Affiliated Hospital Of Guizhou Medical University
Bensen Tang, Doctor
Principal Investigator
Beijing Jishuitan Hosptial Guizhou Hospital
Li Sun, Doctor
Principal Investigator
Guizhou Provincial Peoples Hospital
Xu Cai, Doctor
Principal Investigator
Beijing Tsinghua Changgeng Hospital
Xin Wang, Doctor
Principal Investigator
Yantai Yuhuangding Hospital
Huiwu Li, Doctor
Principal Investigator
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported